Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report.

The present case report describes a postmenopausal patient with hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer, who experienced progression of disease in bilateral lungs, lymph nodes and the liver under previous endocrine therapy and trastuzumab. Following the failure of two lines of endocrine-based treatment, the patient was administered the combined treatment of everolimus, trastuzumab and exemestane following surgical resection of the liver metastasis. A durable partial remission was achieved, which has continued for >27 months. This prominent clinical outcome in this patient demonstrates that the combined administration of endocrine therapy, trastuzumab and everolimus is clinically effective, and may induce long-term remission in patients with HR+/HER2+ metastatic breast cancer.

[1]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[2]  Qingyuan Zhang,et al.  Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. , 2015, The Lancet. Oncology.

[3]  Shiuan Chen,et al.  Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  J. Dering,et al.  In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response , 2015, Breast Cancer Research and Treatment.

[5]  P. Neven,et al.  Everolimus in acute kidney injury in a patient with breast cancer: a case report , 2014, Journal of Medical Case Reports.

[6]  C. Isaacs,et al.  Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Oncology.

[7]  M. Dowsett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. González-Angulo,et al.  Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. , 2013, Cancer treatment reviews.

[9]  G. Mariani,et al.  Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. , 2013, Current cancer drug targets.

[10]  L. Skoog,et al.  Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit , 2012, Breast Cancer Research and Treatment.

[11]  Jia Luo,et al.  Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. , 2012, Cancer research.

[12]  I. Ray-Coquard,et al.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Kuerer,et al.  Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. , 2012, Surgery.

[14]  M. Beckmann,et al.  Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. , 2012, Breast.

[15]  T. Chua,et al.  Hepatic resection for metastatic breast cancer: a systematic review. , 2011, European journal of cancer.

[16]  C. Osborne,et al.  Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient , 2011, Clinical Cancer Research.

[17]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[18]  M. Dowsett,et al.  EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy , 2010, British Journal of Cancer.

[19]  P. Schirmacher,et al.  Liver Resection for Multimodal Treatment of Breast Cancer Metastases: Identification of Prognostic Factors , 2010, Annals of Surgical Oncology.

[20]  J. Mackey,et al.  Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Saeed Sadeghi,et al.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Ellis,et al.  Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Greil,et al.  Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Jack Cuzick,et al.  Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Schiff,et al.  Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.

[27]  M. Ellis,et al.  The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers , 2007, Breast Cancer Research and Treatment.

[28]  R. Gelber,et al.  First--select the target: better choice of adjuvant treatments for breast cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  S. Johnston.  Clinical Efforts to Combine Endocrine Agents with Targeted Therapies against Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 and Mammalian Target of Rapamycin in Breast Cancer , 2006, Clinical Cancer Research.

[30]  A. Giuliano,et al.  The utility of estrogen receptor, progesterone receptor, and Her-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases. , 2006, American journal of surgery.

[31]  J. Cuzick,et al.  Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Schiff,et al.  Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[34]  M. Ellis.  Overcoming endocrine therapy resistance by signal transduction inhibition. , 2004, The oncologist.

[35]  A. Jones.  Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why? , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  G. Hortobagyi,et al.  A role for curative surgery in the treatment of selected patients with metastatic breast cancer. , 2003, The oncologist.

[37]  W. Carney,et al.  Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D B Evans,et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Buzdar.  Endocrine therapy in the treatment of metastatic breast cancer. , 2001, Seminars in oncology.

[41]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[42]  L. Norton,et al.  International consensus guidelines for advanced breast cancer ( ABC 1 ) , 2012 .

[43]  J. Thigpen.  Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer , 2012 .

[44]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). , 2010, Archives of pathology & laboratory medicine.

[45]  F. Ciardiello,et al.  AMeta-Analysis on the Interaction between HER-2 Expression and Response to EndocrineTreatment in Advanced Breast Cancer , 2005 .

[46]  C. Jordan.  Historical perspective on hormonal therapy of advanced breast cancer. , 2002, Clinical therapeutics.